Peptide · Fact sheet

Tesamorelin

Also known as Egrifta SV

Tesamorelin has a specific FDA-approved use in adults with HIV and lipodystrophy. That narrow approval should not be stretched into a general anti-aging, bodybuilding, or weight-loss claim.

FDA approved for specific usesStrong human evidence for approved uses

What is Tesamorelin?

Tesamorelin is a manufactured analog of growth hormone-releasing factor. It signals the pituitary gland and affects the growth-hormone pathway.

Its approved use addresses excess abdominal fat associated with HIV lipodystrophy in adults.

Benefits & claims

People sometimes encounter tesamorelin in discussions of body composition, growth hormone, or aging.

Those discussions often omit that FDA approval is limited to a defined HIV-related condition and that the label says it is not indicated for weight-loss management.

What the evidence supports

  • Clinical trials support reduction in visceral abdominal fat for the labeled population.
  • That outcome does not establish broad weight-loss, longevity, or performance benefits.
Research areas
  • HIV-associated lipodystrophy
  • Visceral abdominal fat
  • Metabolic measures
  • Other metabolic or liver outcomes studied in defined research settings

Dosage & frequency

Product-specific label information

Tesamorelin regimens are formulation-specific: Egrifta SV and Egrifta WR have different daily amounts and are not substitutable.

Egrifta SV

Adults with excess abdominal fat in HIV-associated lipodystrophy

Amount
1.4 mg
Frequency
Once daily
Route studied or labeled
Subcutaneous

Formulation-specific amount.

Egrifta WR

Adults with excess abdominal fat in HIV-associated lipodystrophy

Amount
1.28 mg
Frequency
Once daily
Route studied or labeled
Subcutaneous

Not substitutable with Egrifta SV.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Egrifta SV plasma half-life
Mean eight minutes after a single 1.4 mg dose in healthy subjects; not the duration of metabolic effect.

Formulation differences

  • The label is for excess abdominal fat in adults with HIV-associated lipodystrophy, not general weight loss.

Interactions & precautions

  • GH-mediated changes can affect drug metabolism and glucocorticoid replacement; the label also addresses glucose intolerance.

What is still unresolved

  • Benefits and safety outside HIV-associated lipodystrophy remain unestablished.

Side effects & risks

  • The label includes contraindications and warnings involving malignancy, pregnancy, elevated IGF-1, glucose intolerance or diabetes, hypersensitivity, and fluid retention.
  • Injection-site reactions and musculoskeletal symptoms may occur.
  • Effects of long-term treatment on cardiovascular safety have not been established in the label.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Strong human evidence for approved uses

Randomized trials support the narrow approved indication. Evidence for unrelated wellness goals is not equivalent.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 3 sourced accounts by reported effect.

Weight: reported experiences

Mixed account · personal report

Leaner appearance and better sleep during combined use

An author described less lower-abdominal fat, good sleep and sulfur-tasting burps while using tesamorelin with retatrutide.

Reported use in this account

Product
Product labeled tesamorelin
Amount
Not specified clearly
Frequency
Five days per week, as reported
Route
Not specified clearly
Duration
About eight weeks

Other exposures described: Retatrutide; Caffeinated pre-workout drink

Retatrutide exposure, diet and an ongoing weight-loss effort changed together. Appearance does not verify loss of visceral fat.

Read the original account

Approval status

Egrifta SV is FDA approved to reduce excess abdominal fat in HIV-infected adult patients with lipodystrophy. It is not indicated for general weight-loss management.

Approved uses

  • Reduction of excess abdominal fat in adults with HIV and lipodystrophy

FDA approved for a narrow HIV-related use

Tesamorelin's approval is tied to the Egrifta label and HIV-associated lipodystrophy. It should not be generalized to ordinary weight loss or anti-aging claims.

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Long-term cardiovascular outcomes
  • Benefits and harms for people outside the approved population
  • Whether changes in abdominal fat translate to every outcome a reader may care about

Summary

Tesamorelin is a real approved medicine with a narrow use. Its approval is not evidence for general weight loss, anti-aging, or athletic-performance claims.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. fdaFDA prescribing information: Egrifta SV

    Official label describing indication, limitations, and safety information.

  2. clinical trialsClinicalTrials.gov: TH9507 in HIV-associated lipodystrophy

    Registry record for a Phase 3 tesamorelin study in HIV-associated lipodystrophy.

  3. clinical trialsClinicalTrials.gov: TH9507 extension study

    Registry record for a tesamorelin extension study in HIV-associated lipodystrophy.

  4. pubmedTesamorelin pooled Phase 3 analysis

    Peer-reviewed report of tesamorelin trial findings in HIV-associated lipodystrophy.

  5. fdaFDA prescribing information: Egrifta WR

    Primary source for the practical reference information.

How we assess sources · Suggest a correction